drugset / Trial / NCT01090453
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants
RandomizedParallel-groupOpen-labelPrevention
Summary
This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083 vaccine co-administered with Prevenar 13® at 2, 4 and 12 months of age and with Rotarix™ at 2 and 4 months of age.
Timeline
- Start
- 2010-05-17
- Primary completion
- 2011-10-11
- Completion
- 2011-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK2202083A | Vaccine | — | Intramuscular |
| Comparator | Infanrix hexa | Vaccine | — | Intramuscular |
| Comparator | Menjugate | Vaccine | — | Intramuscular |
| Background | Prevnar 13 | Vaccine | — | Intramuscular |
| Background | Rotarix | Vaccine | — | Oral |